PriceTargets.com logo

Kestra Medical Technologies - KMTS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $27.40
  • Forecasted Upside: 15.08%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$23.81 As of 04/22/2026 05:00 PM ET
▲ +0.62 (2.67%)

This chart shows the closing price for KMTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kestra Medical Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KMTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KMTS

Analyst Price Target is $27.40
▲ +15.08% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Kestra Medical Technologies in the last 3 months. The average price target is $27.40, with a high forecast of $32.00 and a low forecast of $17.00. The average price target represents a 15.08% upside from the last price of $23.81.

This chart shows the closing price for KMTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Kestra Medical Technologies. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/24/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/22/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/23/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/22/2026

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/9/2026The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$22.00 ➝ $17.00
4/7/2026BTIG ResearchReiterated RatingBuy ➝ Buy$32.00
3/25/2026BTIG ResearchReiterated RatingBuy ➝ Buy$32.00
3/23/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/18/2026BTIG ResearchReiterated RatingBuy ➝ Buy$32.00
1/16/2026The Goldman Sachs GroupSet Target$24.00
1/9/2026The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$27.00
12/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/18/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/13/2025The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$22.00 ➝ $25.00
12/12/2025Stifel NicolausSet Target$30.00
12/12/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$27.00 ➝ $28.00
12/12/2025Piper SandlerBoost TargetOverweight ➝ Overweight$27.00 ➝ $30.00
11/18/2025BTIG ResearchInitiated CoverageBuy$32.00
10/8/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/27/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
7/17/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$28.00 ➝ $27.00
4/16/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$24.00 ➝ $23.00
3/31/2025Bank of AmericaInitiated CoverageBuy$30.00
3/31/2025Wolfe ResearchInitiated CoverageOutperform$29.00
3/31/2025Wells Fargo & CompanyInitiated CoverageOverweight$28.00
3/31/2025Piper SandlerInitiated CoverageOverweight$27.00
3/31/2025The Goldman Sachs GroupInitiated CoverageNeutral$24.00
3/31/2025Stifel NicolausInitiated CoverageBuy$28.00
(Data available from 4/22/2021 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2025
  • 3 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/21/2026
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2026
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2026

Current Sentiment

  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Kestra Medical Technologies logo
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation